Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COVID-19 Vaccine Sponsors’ Pledge To Wait For Phase III Helps US FDA

Executive Summary

The move reduces the pressure on the companies to rush development, but also relieves burden on the FDA to approve a candidate too soon.

You may also be interested in...



Biden's COVID-19 Advisory Board Bodes Well For Science-Driven FDA

Two prominent former US FDA officials are a part of the president-elect’s new COVID-19 advisory board. Biden’s emphasis on scientific independence, including a commitment to publicly release vaccine trial data, could help restore public confidence in the agency and coming COVID-19 vaccines.

COVID-19 Vaccines Blaze New Path In the History Of Vaccine Development

Vaccine experts, including R&D leaders at Pfizer and Sanofi, describe what has been unique in developing a vaccine for the novel coronavirus, lessons learned from previous vaccines, and challenges that lie ahead.

‘I Was Disappointed,’ Pfizer CEO Bourla Says Of US Presidential Debate

Pfizer CEO Albert Bourla said he is disappointed in the US politicization of a COVID-19 vaccine in a letter to employees. We are moving at the speed of science,’ he said.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS142871

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel